Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 4/20 | 0.51 |
| ▸ | ABL1 | P00519 | 4/20 | 0.47 |
| ▸ | BCR | P11274 | 4/20 | 0.47 |
| ▸ | DDR2 | Q16832 | 9/20 | 0.45 |
| ▸ | FGFR1 | P11362 | 7/20 | 0.45 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13435317 | 0.88 | PAK1 (0.44) | MAPK14ABL1BCRCHEK1KCNH2 | |
| SCHEMBL3522651 | 0.84 | MAPK14 (0.43) | MAPK14ABL1BCRCHEK1KCNH2 | |
| SCHEMBL4215237 | 0.84 | MAP2K4 (0.53) | MAPK14ABL1BCRDDR2FGFR1 | |
| SCHEMBL4225514 | 0.83 | DDR2 (0.50) | MAPK14ABL1BCRDDR2FGFR1 | |
| SCHEMBL4215363 | 0.83 | TRPA1 (0.51) | MAPK14DDR2FGFR1 | |
| SCHEMBL4219480 | 0.82 | DDR2 (0.51) | MAPK14ABL1DDR2FGFR1 | |
| SCHEMBL4224187 | 0.82 | DDR2 (0.47) | MAPK14ABL1BCRDDR2FGFR1 | |
| SCHEMBL13948930 | 0.82 | TRPA1 (0.50) | MAPK14DDR2FGFR1 | |
| SCHEMBL4212929 | 0.82 | DDR2 (0.49) | MAPK14ABL1BCRDDR2FGFR1 | |
| SCHEMBL3525146 | 0.80 | MAPK14 (0.56) | MAPK14ABL1BCRDDR2FGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7687532-B2 | Fused heteroaryl derivatives for use as p38 kinase inhibitors in the treatment of I.A. rheumatoid arthritis | GLAXOSMITHKLINE LLC (US) | 2010-03-30 | — | — | US | disclosed |
| US-7687532-B2 | Fused heteroaryl derivatives for use as p38 kinase inhibitors in the treatment of I.A. rheumatoid arthritis | GLAXOSMITHKLINE LLC (US) | 2010-03-30 | — | — | US | disclosed |
| US-7687532-B2 | Fused heteroaryl derivatives for use as p38 kinase inhibitors in the treatment of I.A. rheumatoid arthritis | GLAXOSMITHKLINE LLC (US) | 2010-03-30 | — | — | US | disclosed |
| US-20090023725-A1 | Fused Heteroaryl Derivatives for Use as P38 Kinase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2009-01-22 | — | — | US | disclosed |
| US-20090023725-A1 | Fused Heteroaryl Derivatives for Use as P38 Kinase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2009-01-22 | — | — | US | disclosed |
| US-20090023725-A1 | Fused Heteroaryl Derivatives for Use as P38 Kinase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2009-01-22 | — | — | US | disclosed |
| EP-1708996-B1 | FUSED HETEROYRAL DERIVATIVES FOR USE AS P38 KINASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2008-08-27 | — | — | EP | disclosed |
| EP-1708996-B1 | FUSED HETEROYRAL DERIVATIVES FOR USE AS P38 KINASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2008-08-27 | — | — | EP | disclosed |
| US-20070142372-A1 | Fused heteroaryl derivatives for use as p38 kinase inhibitors in the treatment of i.a. rheumatoid arthritis | GLAXOSMITHKLINE LLC | 2007-06-21 | — | — | US | disclosed |
| US-20070142372-A1 | Fused heteroaryl derivatives for use as p38 kinase inhibitors in the treatment of i.a. rheumatoid arthritis | GLAXOSMITHKLINE LLC | 2007-06-21 | — | — | US | disclosed |
| US-20070142372-A1 | Fused heteroaryl derivatives for use as p38 kinase inhibitors in the treatment of i.a. rheumatoid arthritis | GLAXOSMITHKLINE LLC | 2007-06-21 | — | — | US | disclosed |
| EP-1745038-A1 | FUSED HETEROARYL DERIVATIVES FOR USE AS P38 KINASE INHIBITORS IN THE TREATMENT OF I.A. RHEUMATOID ARTHRITIS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-01-24 | — | — | EP | disclosed |
| EP-1708996-A1 | FUSED HETEROYRAL DERIVATIVES FOR USE AS P38 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-10-11 | — | — | EP | disclosed |
| WO-2005073219-A1 | FUSED HETEROARYL DERIVATIVES FOR USE AS P38 KINASE INHIBITORS IN THE TREATMENT OF I.A. RHEUMATOID ARTHRITIS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-08-11 | — | — | WO | disclosed |
| WO-2005073189-A1 | FUSED HETEROYRAL DERIVATIVES FOR USE AS P38 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023725-A1 | Fused Heteroaryl Derivatives for Use as P38 Kinase Inhibitors | MAPK1, MAPKAPK2, MAPK7 | MAPK14 19/4885ABL1 170/4885BCR 415/4885 |
| US-20070142372-A1 | Fused heteroaryl derivatives for use as p38 kinase inhibitors in the treatment of i.a. rheumatoid arthritis | CNKSR1, MAPK1, MAPK7 | MAPK14 10/4885ABL1 423/4885BCR 1071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.